ONE+ uses Dexcom’s established sensor design, with the company incorporating feedback from users and healthcare professionals to build it. The company said this ensured an easy-to-use, highly effective CGM experience for people treating type 1 or type 2 diabetes with insulin.
This version of the platform utilizes the latest-generation G7 sensor, while the previous version used the G6. CEO Kevin Sayer told Drug Delivery Business News this year that he expected to complete this transfer during the first quarter of 2024.
ONE+ also adds certain notes at certain moments, like meals, insulin administration and sports activities. The system replaces the traditional fingersticks to provide a clear picture of how daily choices affect glucose levels.
Dexcom began rolling out the system in Spain, Belgium and Poland in February. It followed that up with rollouts in more European locations in March. In some countries, the system replaces the previous-generation Dexcom One sensor, which originally launched in the UK in 2022.
Teri Lawver, Dexcom EVP and CCO, previously said: “Dexcom ONE+ incorporates our best-in-class technology and a range of features that we know will be well-received by the diabetes community.”
Dexcom launches tool for supporting type 2 diabetes
The San Diego-based company also unveiled its State of Type 2 report, a first-of-its-kind look at the Type 2 diabetes landscape. The report examines the preferences and behaviors of those living with the condition and their caretakers and healthcare professionals.
Dexcom hopes the report can provide a valuable resource for supporting type 2 diabetes, while ONE+ can offer a management solution specifically suited to those with type 2.
The first-ever State of Type 2 report says that 49% of individuals with type 2 were unaware of the condition’s effects when diagnosed. Additionally, 63% say they encounter difficulties in diabetes management, and 42% of people with diabetes and caregivers surveyed say living with type 2 negatively impacted their mental health or that of the person they care for.
Dexcom reports anxiety (61%) and depression (52%) as the most commonly reported effects of living with type 2 diabetes. Close to half of those surveyed (48%) believe monitoring their glucose levels would help better manage their condition. Additionally, 39% feel that greater knowledge about available care options would benefit them.
The company says a recent study showed a link between real-time CGM usage (like Dexcom ONE+) and improved condition management.
“The Dexcom State of Type 2 report reveals that people trying to manage their type 2 diabetes face significant impacts on all areas of their lives including, and perhaps particularly, their mental health,” says Karen Baxter, VP, Northern Europe, South Africa, Israel, and Malta at Dexcom. “We’re proud to have developed a sensor that addresses the unmet needs of the type 2 community. Feedback from users and healthcare professionals already using Dexcom ONE+ indicates that the sensor is easy to use and motivational, as it provides a clearer understanding of how food and exercise choices affect glucose levels.
“Seeing real-time feedback can help alleviate the frustration many people, especially those with type 2 diabetes, experience in understanding and managing their condition.”
